

CITATION REPORT

List of articles citing

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

DOI: 10.1016/s1470-2045(20)30180-7
Lancet Oncology, The, 2020, 21, 957-968.

Source: <https://exaly.com/paper-pdf/76769938/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
96	New approaches for targeting platinum-resistant ovarian cancer. <i>Seminars in Cancer Biology</i> , 2021 , 77, 167-181	12.7	13
95	Exploiting the Microhomology-Mediated End-Joining Pathway in Cancer Therapy. <i>Cancer Research</i> , 2020 , 80, 4593-4600	10.1	18
94	Combinational dual drug delivery system to enhance the care and treatment of gastric cancer patients. <i>Drug Delivery</i> , 2020 , 27, 1491-1500	7	4
93	Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study. <i>Pharmaceuticals</i> , 2020 , 13,	5.2	5
92	Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences. <i>Cancer Treatment Reviews</i> , 2020 , 90, 102090	14.4	6
91	Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targets. <i>Seminars in Cancer Biology</i> , 2021 , 77, 29-41	12.7	12
90	Biomarker-Guided Development of DNA Repair Inhibitors. <i>Molecular Cell</i> , 2020 , 78, 1070-1085	17.6	67
89	The Challenge of Combining Chemo- and Radiotherapy with Checkpoint Kinase Inhibitors. <i>Clinical Cancer Research</i> , 2021 , 27, 937-962	12.9	5
88	The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response. <i>British Journal of Cancer</i> , 2021 , 124, 857-859	8.7	11
87	SLFN11 informs on standard of care and novel treatments in a wide range of cancer models. <i>British Journal of Cancer</i> , 2021 , 124, 951-962	8.7	14
86	Major clinical research advances in gynecologic cancer in 2020. <i>Journal of Gynecologic Oncology</i> , 2021 , 32, e53	4	3
85	Precise engineering of hybrid molecules-loaded macromolecular nanoparticles shows and antitumor efficacy toward the treatment of nasopharyngeal cancer cells. <i>Drug Delivery</i> , 2021 , 28, 776-786	7	7
84	ATR Inhibition as an Attractive Therapeutic Resource against Cancer. <i>Cancer Discovery</i> , 2021 , 11, 14-16	24.4	2
83	Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2021 , 397, 281-292	40	32
82	An mRNA expression-based signature for oncogene-induced replication-stress.		
81	A Decade of FDA-Approved Drugs (2010-2019): Trends and Future Directions. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 2312-2338	8.3	41
80	Clinical Candidates Targeting the ATR-CHK1-WEE1 Axis in Cancer. <i>Cancers</i> , 2021 , 13,	6.6	13

79	Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer. <i>Drug Resistance Updates</i> , 2021 , 55, 100744	23.2	12
78	DNA damage response inhibitors: An avenue for TNBC treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021 , 1875, 188521	11.2	5
77	Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication. <i>Cell Reports</i> , 2021 , 35, 108940	10.6	28
76	Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine + cisplatin in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021 , 125, 510-519	8.7	16
75	Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021 , 125, 520-527	8.7	9
74	Kinase Inhibitors of DNA-PK, ATM and ATR in Combination with Ionizing Radiation Can Increase Tumor Cell Death in HNSCC Cells While Sparing Normal Tissue Cells. <i>Genes</i> , 2021 , 12,	4.2	3
73	VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 1561-1571	6.1	0
72	Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 695-707	5.9	1
71	CD44v6-O-MWNTS-Loaded Gemcitabine and CXCR4 siRNA Improves the Anti-tumor Effectiveness of Ovarian Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 687322	5.7	1
70	Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores. <i>ESMO Open</i> , 2021 , 6, 100229	6	2
69	Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 1536-1543	13.4	5
68	amplification among metastatic sites in patients with gynecologic high-grade serous carcinoma. <i>Gynecologic Oncology Reports</i> , 2021 , 37, 100850	1.3	0
67	A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. <i>Nature Communications</i> , 2021 , 12, 5574	17.4	2
66	Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11. <i>Cancers</i> , 2021 , 13,	6.6	1
65	Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors. <i>Cancer Treatment Reviews</i> , 2021 , 101, 102298	14.4	1
64	Targeting mutant p53 for cancer therapy: direct and indirect strategies. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 157	22.4	21
63	Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021 , 379, 343-357	4.7	0
62	Inappropriate censoring in Kaplan-Meier analyses. <i>Lancet Oncology</i> , 2021 , 22, 1358-1360	21.7	0

61	Targeting the replication stress response through synthetic lethal strategies in cancer medicine. <i>Trends in Cancer</i> , 2021 , 7, 930-957	12.5	11
60	Metabolic reprogramming and immunity in cancer. 2022 , 137-196		
59	Engineering of Self-assembly Polymers Encapsulated with Dual Anticancer Drugs for the Treatment of Endometrial Cancer. <i>Journal of Cluster Science</i> , 1	3	
58	Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021 , 163, 246-253	4.9	8
57	A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade. <i>Annual Review of Medicine</i> , 2021 ,	17.4	0
56	Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response. <i>British Journal of Cancer</i> , 2021 , 125, 1666-1676	8.7	2
55	Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance. <i>Current Opinion in Obstetrics and Gynecology</i> , 2021 , 33, 19-25	2.4	2
54	Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies.. <i>Current Oncology</i> , 2021 , 28, 4894-4928	2.8	
53	Early Alterations Shape Gastric and Esophageal Cancer Development. <i>Cancers</i> , 2021 , 13,	6.6	0
52	A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2021 , 163, 19-26	5.9	2
51	Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance.. 2021 , 4, 984-995		
50	An mRNA expression-based signature for oncogene-induced replication-stress.. <i>Oncogene</i> , 2022 ,	9.2	0
49	Therapeutic Targeting of DNA Damage Response in Cancer.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
48	Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 168, 103539	7	4
47	RP-3500: A Novel, Potent and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors.. <i>Molecular Cancer Therapeutics</i> , 2021 ,	6.1	3
46	Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents.. <i>Cancers</i> , 2022 , 14,	6.6	4
45	A case of primary vulvar serous carcinoma showing pruritic vulvar rash.. <i>Asian Journal of Surgery</i> , 2022 , 45, 1272-1272	1.6	
44	Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer (Review).. <i>Oncology Reports</i> , 2022 , 47,	3.5	2

43	Identification of the Signature Genes and Network of Reactive Oxygen Species Related Genes and DNA Repair Genes in Lung Adenocarcinoma.. <i>Frontiers in Medicine</i> , 2022 , 9, 833829	4.9	1
42	Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. <i>Genes and Diseases</i> , 2022 ,	6.6	11
41	DNA damage response inhibition-based combination therapies in cancer treatment: Recent advances and future directions. <i>Aging and Cancer</i> , 2022 , 3, 44-67	0.2	0
40	Therapeutic strategies to overcome cisplatin resistance in ovarian cancer.. <i>European Journal of Medicinal Chemistry</i> , 2022 , 232, 114205	6.8	5
39	Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.. <i>Npj Breast Cancer</i> , 2022 , 8, 45	7.8	1
38	Prise en charge médicale de la récurrence du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer.. <i>Bulletin Du Cancer</i> , 2021 , 108, S22-S32	2.4	
37	DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?. <i>Biomedicines</i> , 2021 , 10,	4.8	0
36	Innovative therapies to tackle platinum-resistant ovarian cancer.. <i>Nature</i> , 2021 , 600, S45-S47	50.4	0
35	Preclinical modeling of leiomyosarcoma identifies susceptibility to transcriptional CDK inhibitors through antagonism of E2F-driven oncogenic gene expression.. <i>Clinical Cancer Research</i> , 2022 ,	12.9	0
34	Role of EMT in the DNA damage response, double-strand break repair pathway choice and its implications in cancer treatment.. <i>Cancer Science</i> , 2022 ,	6.9	0
33	ATR inhibition sensitizes liposarcoma to doxorubicin by increasing DNA damage.. <i>American Journal of Cancer Research</i> , 2022 , 12, 1577-1592	4.4	
32	Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma. <i>Computational and Mathematical Methods in Medicine</i> , 2022 , 2022, 1-8	2.8	3
31	Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations. <i>Current Opinion in Oncology</i> , Publish Ahead of Print,	4.2	1
30	The role of imaging in targeted delivery of nanomedicine for cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2022 , 114447	18.5	2
29	Pharmacotherapeutic treatment options for recurrent epithelial ovarian cancer.		
28	The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response. 2022 , 11, 2361		0
27	Processing DNA lesions during mitosis to prevent genomic instability. 2022 , 50, 1105-1118		1
26	Therapy for Recurrent High-Grade Epithelial Ovarian Cancer: The Current Status and Future Trends.		0

25	AZD6738 Inhibits fibrotic response of conjunctival fibroblasts by regulating checkpoint kinase 1/P53 and PI3K/AKT pathways. 13,	0
24	Targeting replication stress in cancer therapy.	2
23	SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance. 2022 , 82, 3962-3973	0
22	Delineating the SARS-CoV-2 Induced Interplay between the Host Immune System and the DNA Damage Response Network. 2022 , 10, 1764	0
21	Tumor-specific radiosensitizing effect of the ATM inhibitor AZD0156 in melanoma cells with low toxicity to healthy fibroblasts.	1
20	Exploring the DNA damage response pathway for synthetic lethality.	0
19	Role of protein phosphorylation in cell signaling, disease, and the intervention therapy. 2022 , 3,	1
18	Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition.	0
17	ATR Inhibitors in Platinum-Resistant Ovarian Cancer. 2022 , 14, 5902	1
16	Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises. 2022 , 14, 6257	0
15	Targeting DNA damage response pathways in cancer.	9
14	ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma. 2022 , 7,	1
13	DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities. 2023 , 15, 448	0
12	Targeting the DNA damage response for cancer therapy.	0
11	Glutamine metabolism targeting liposomes for synergistic chemosensitization and starvation therapy in ovarian cancer. 2022 ,	0
10	CCNE1 Amplification as a Therapeutic Target.	0
9	The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.	0
8	Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer. 2023 , 15, 175883592311576	0

- 7 Overcoming PARP inhibitor resistance in ovarian cancer. **2023**, 33, 364-376
- 6 Construction of Metastasis-Specific Regulation Network in Ovarian Cancer Based on Prognostic Stemness-Related Signatures.
- 5 Replicative stress in gastroesophageal adenocarcinoma is associated with chromosomal instability and sensitivity to DNA damage response inhibitors.
- 4 Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy.
- 3 Synergistic anticancer activity of combined ATR and ribonucleotide reductase inhibition in Ewing's sarcoma cells.
- 2 Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance.
- 1 Emerging strategies for cancer therapy by ATR inhibitors.